
Ergon Capital Partners buys ELITech
Ergon Capital Partners has acquired French manufacturer and distributor of in vitro diagnostic equipment and reagents ELITech Group.
The deal value has not been disclosed but the mid-cap investor financed the acquisition through its Ergon Capital Partners III fund.
Previous backers BNP Paribas Développement, Idia Participations, Naxicap and Synergie Finance all reinvested and continue to hold a stake in the company.
Elitech is headquartered in Salon de Provence and was formed in 2005 through the merger between the diagnostic divisions of biochemistry groups Biotech International and LDH.
The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.
If you have any information regarding this transaction, please contact Gregoire Gille on +44 20 7484 9824 or gregoire.gille@incisivemedia.com
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater